Trial Profile
A phase 2b/3, multi-center, observer-blind, controlled study of the safety, tolerability and immunogenicity of Novartis meningococcal B recombinant vaccine administered to healthy adolescents aged 11-17 years according to different vaccination schedules.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group B (Primary)
- Indications Meningococcal group B infections; Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Novartis
- 25 Oct 2020 Results presented at the IDWeek 2020
- 23 Apr 2012 Actual end date for the extension trial (NCT01148524) is now Jan 2012.
- 23 Apr 2012 Actual end date for the extension trial (NCT01148524) is now Jan 2012.